Cargando…
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
BACKGROUND: The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune disease, inflammatory conditions, and Alzheimer’s disease. The safety, tolerability, and mechanisms of action in Parkinson’s disease (PD) during extended use has n...
Autores principales: | Olson, Katherine E., Abdelmoaty, Mai M., Namminga, Krista L., Lu, Yaman, Obaro, Helen, Santamaria, Pamela, Mosley, R. Lee, Gendelman, Howard E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201023/ https://www.ncbi.nlm.nih.gov/pubmed/37217980 http://dx.doi.org/10.1186/s40035-023-00361-1 |
Ejemplares similares
-
Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease
por: Olson, Katherine E., et al.
Publicado: (2021) -
Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease
por: Abdelmoaty, Mai M., et al.
Publicado: (2022) -
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
por: Gendelman, Howard E., et al.
Publicado: (2017) -
Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease
por: Markovic, Milica, et al.
Publicado: (2022) -
Immune senescence in aged APP/PS1 mice
por: Abdelmoaty, Mai M., et al.
Publicado: (2023)